UVA 1 Phototherapy for Vitiligo
Visão geral do estudo
Descrição detalhada
Vitiligo is a chronic acquired disease characterized by well defined white macules and patches affecting the skin and mucous membranes. Mucocutaneous lesions develop secondary to selective destruction of melanocytes. The etiology of vitiligo is largely unknown but more likely to be multifactorial. There are several theories on the pathogenesis of vitiligo including mainly the autoimmune, neurohormonal, and autocytotoxic theories. The autoimmune hypothesis has the strongest evidence with alteration mainly in the cellular immune response.
There are many treatment modalities available for vitiligo, however, none of them cure the disease. These include different topical treatments, phototherapy, surgical therapy, and depigmentation therapy. Narrow-band UVB (NB-UVB) is currently the preferred treatment over topical psoralen and ultraviolet A radiation (PUVA), for patients with vitiligo. However, overall response of vitiligo to NB-UVB has been variable. Ultraviolet A1(UVA1) phototherapy is now useful for a variety of skin diseases, specifically scleroderma. There are only a few studies published on the efficacy of UVA1 in vitiligo.
One of the main side effects of UVA1 is prominent tanning which might be due to melanocyte stimulation. Therefore, the investigators hypothesis is that UVA1 will induce significant skin pigmentation to improve vitiligo. The investigators plan on conducting a prospective single-blind randomized clinical trial to assess efficacy and safety of UVA1 in the treatment of vitiligo.
Study Objectives
- To evaluate the potential for UVA1 to induce repigmentation within vitiligo patches.
- To assess the side effect profile of UVA1 when used in the treatment of vitiligo.
Tipo de estudo
Inscrição (Antecipado)
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
British Columbia
-
Vancouver, British Columbia, Canadá, V5Z 4E8
- Recrutamento
- The Skin Care Center, Vancouver General Hospital
-
Investigador principal:
- Harvey Lui, MD FRCPC
-
Contato:
- Harvey I Lui, MD FRCPC
- Número de telefone: 68691 16048754111
- E-mail: harvey.lui@ubc.ca
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Age > 18 years.
- Localized or generalized vitiligo that involves a non mucosal or acral site.
- Patients should have a patch of at least 25 cm2 that shows no more than 10% repigmentation as assessed visually
Exclusion Criteria:
- Patients who received treatment for vitiligo within the past 3 weeks.
- Patients known to have a photosensitivity disorder
- History of previous skin cancer.
- History of severe medical illness or immunosuppression.
- Pregnancy or breast-feeding.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Sem intervenção: Sem tratamento (coberto)
|
|
|
Comparador Ativo: UVA1
|
Patients with a vitiligo patch larger than 25cm2 will be recruited. The target patch will be divided into two halves. One half will be shielded by foil and served as control while the other half will be exposed to UVA1. The dose of UVA1 will be 60 J/cm2, 5 times a week for 4 weeks. Patients that have no or less than 10% pigmentation change after 4 weeks will receive UVA1 130J/cm2, 5 times a week for another 4 weeks. The patients with more than 10% pigmentation change will receive UVA1 60 J/cm2, 5times a week for another 4weeks. This will be followed by assessments at 4, 8, and 12 weeks post treatment. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
|---|---|
|
Change in the modified VASI score compared to baseline.
Prazo: assessments at 2, 4, 6, and 8 weeks during treatment then at 4, 8, and 12 weeks post treatment
|
assessments at 2, 4, 6, and 8 weeks during treatment then at 4, 8, and 12 weeks post treatment
|
Medidas de resultados secundários
Medida de resultado |
Prazo |
|---|---|
|
Assessment of side effects in each half including erythema, pruritus, and polymorphous light eruption
Prazo: assessments at 2, 4, 6, and 8 weeks during treatment then at 4, 8, and 12 weeks post treatment
|
assessments at 2, 4, 6, and 8 weeks during treatment then at 4, 8, and 12 weeks post treatment
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Harvey Lui, MD, FRCPC, University of British Columbia
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Antecipado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- H10-02235
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .